PTC Therapeutics, Inc.
vatiquinone
Friedreich’s ataxia
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews vatiquinone for Friedreich’s ataxia around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“Type C meeting with FDA held in April 2026 to discuss vatiquinone study to support NDA resubmission for Friedreich’s ataxia program”